The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Gilead Says It Has No Intention to Scrap License Deal: Carna Bio
Kobe-based biotech Carna Biosciences said on September 9 that it has received confirmation from Gilead Sciences that the US firm has no intention at this time of ending their licensing agreement related to a drug discovery program for DGKα inhibitors.…
To read the full story
BUSINESS
- Daiichi Sankyo Unveils Brand Site for OTC NorLevo Ahead of Launch
January 15, 2026
- Cheplapharm to Take Over Japan MA for UCB’s Myocalm
January 15, 2026
- Meiji-Daito Generic Consortium Expands to Eight Members
January 15, 2026
- Daiichi Launches PIII Datroway Trial in TROP2 Positive NSCLC
January 15, 2026
- Opdivo-Yervoy Combo Expands Label for Colorectal Cancer in Taiwan: Ono
January 15, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…